The Cigna Group (CI) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial performance, exceeding revenue expectations and maintaining robust cash flow. Shareholder returns are significant, and strategic investments are in place. The Q&A section indicates alignment with regulatory expectations and optimistic growth in specialty services. While there are concerns about margin pressures and cash flow conversion, the overall sentiment remains positive due to strong fundamentals and strategic alignment. The positive outlook for the specialty business and shareholder returns further support a positive stock price reaction.
Key Financial Performance
Adjusted Revenue $275 billion for the full year 2025, representing an 11% growth year-over-year. This growth was driven by specialty pharmacy growth and client relationships.
Adjusted Earnings Per Share (EPS) $29.84 for the full year 2025, a 9% increase year-over-year. This increase reflects sustained earnings growth and disciplined execution.
Evernorth Specialty and Care Services Revenue $26.7 billion for the fourth quarter, a 14% increase year-over-year. This growth was supported by robust specialty volumes and rising biosimilar use.
Evernorth Pharmacy Benefit Services Revenue $36.3 billion for the fourth quarter, reflecting solid performance and strategic investments, including initiatives to enhance patient experience.
Cigna Healthcare Adjusted Revenue $11.2 billion for the fourth quarter 2025, slightly exceeding expectations due to favorable net investment income offsetting modestly higher medical costs.
Cash Flow from Operations $9.6 billion for the full year 2025, reflecting strong operational performance and disciplined capital management.
Shareholder Returns $5 billion returned to shareholders in 2025 through dividends and share repurchases, demonstrating a commitment to shareholder value.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Pharmacy Benefit Model: Introduced a transformative rebate-free pharmacy benefits model to enhance affordability and transparency for customers and patients.
Clearity Solution: Launched Clearity, a new offering in Cigna Healthcare, providing cost transparency, simplified co-pay structure, and integrated digital experiences for pharmacy, dental, and supplemental health.
AI-powered Digital Tools: Expanded suite of AI-powered tools for personalized customer experiences, including provider matching and real-time cost tracking.
Specialty Capabilities Expansion: Expanded specialty capabilities to serve hospitals and health systems through investment in Shields Health Solutions.
Fertility Drug Accessibility: Collaborated with TrumpRx and Evernorth to make fertility treatments more accessible at the lowest available cash price.
Biosimilar and Specialty Generics: Focused on leveraging biosimilars and specialty generics to drive affordability and expand market reach.
Customer Net Promoter Score: Improved customer Net Promoter Score year-over-year across largest businesses.
Prior Authorization Reduction: Reduced prior authorizations by 15% to minimize administrative burden for providers.
Digital Engagement: Increased digital registrations and decreased call volumes, enhancing operational efficiency.
Medicare Business Divestiture: Completed the sale of Cigna Healthcare's Medicare business to focus on sustainable growth areas.
FTC Settlement: Resolved FTC matters with a $7 billion settlement to lower insulin prices and reduce brand-name medication costs over 10 years.
Portfolio Shaping: Shifted focus to high-growth specialty and care services, now accounting for 35% of the company’s portfolio.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
FTC Settlement and Regulatory Compliance: The company has reached a $7 billion settlement with the FTC regarding pharmacy benefits business, including insulin lawsuits and ongoing investigations. This settlement could impose financial strain and operational adjustments to comply with the terms.
Rising Healthcare Costs: Healthcare costs are increasing due to aging population, chronic conditions, and rising costs of hospital stays and new drug launches. This could impact affordability and profitability.
Medical Cost Ratio (MCR) Challenges: Higher medical costs in 2025, equating to approximately $50 million, and elevated cost trend environment expected in 2026 could pressure margins.
Pharmacy Benefit Model Transformation: The company is investing heavily in a new rebate-free pharmacy benefits model, which requires significant infrastructure spending and could face implementation risks.
Supply Chain and Cost Drivers: Despite increased supply in healthcare, costs are rising, particularly for hospital stays and specialty drugs, which could strain financial performance.
Economic and Market Volatility: Dynamic environment and volatility in markets could impact financial performance and strategic execution.
Membership and Revenue Growth Challenges: Lower membership in national accounts and individual exchange business expected in 2026 could impact revenue growth.
Debt and Capitalization: Debt-to-capitalization ratio remains at 43%, with a target of 40%, indicating ongoing financial leverage that needs to be managed.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Adjusted EPS for 2026: The company projects an adjusted EPS of at least $30.25 for the full year 2026, reflecting sustained growth and strength.
Consolidated Adjusted Revenues for 2026: Expected to be approximately $280 billion for the full year 2026.
Evernorth Adjusted Earnings for 2026: Projected to be at least $6.9 billion, with investment spending for the rebate-free model weighted towards the back half of the year.
Cigna Healthcare Adjusted Earnings for 2026: Expected to be at least $4.5 billion, with earnings seasonality consistent with prior years.
Medical Care Ratio (MCR) for 2026: Anticipated to range between 83.7% and 84.7%, reflecting pricing actions and an elevated cost trend environment.
Total Medical Customers for 2026: Projected to be approximately 18.1 million at year-end, with growth in middle, select, and international markets offset by declines in national accounts and individual exchange business.
Adjusted SG&A Ratio for 2026: Expected to remain at approximately 5%, consistent with 2025 levels.
Cash Flow from Operations for 2026: Projected to be approximately $9 billion, with the majority realized in the second half of the year.
Capital Deployment for 2026: Approximately $1.3 billion allocated to capital expenditures and $1.6 billion to shareholder dividends.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividends in 2025: Cigna returned $1.6 billion to shareholders via dividends in 2025.
2026 Dividend Outlook: Cigna expects to deploy approximately $1.6 billion to shareholder dividends in 2026, reflecting an increased quarterly dividend of $1.56 per share.
Share Repurchase in 2025: Cigna repurchased 11.9 million shares of common stock for approximately $3.6 billion in 2025.
2026 Share Repurchase Outlook: Cigna plans to continue share repurchases in 2026, with full year weighted average shares outstanding expected to be in the range of 261 million to 265 million shares.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you discuss the margin profile of the PBM after the new legislation and the financial implications of moving the GPO back to the U.S.?
A:David Cordani stated that the margin profile of the PBM will remain similar, with no change in the growth algorithm for the Pharmacy Benefit Services business. The move of the GPO back to the U.S. could have an outside impact of up to 1% on the effective tax rate over time, which is manageable given the company's long-term earnings growth algorithm of 10%-14%.
Q:Do you feel your PBM model is fully aligned with regulatory and policymaker expectations, or are there residual regulatory battles ahead?
A:David Cordani expressed confidence that their new PBM model is aligned with regulatory and policymaker expectations. The model is customer-first, no rebate, no spread, and fully transparent. Brian Evanko added that the Cigna Healthcare fully insured book will adopt the new model in 2027, and at least 50% of Evernorth business will adopt it by 2028.
Q:What is the timing of the settlement requirements, and how does it align with the launch of the new rebate-free model?
A:David Cordani clarified that the new rebate-free model will be the standard offering by 2028, and there is no liability if adoption rates vary. Brian Evanko confirmed that the FTC agreement does not change the launch plan for the rebate-free model, which includes Price Assure Technology to guarantee the lowest possible price for patients.
Q:Why isn't the MLR in 2026 expected to improve despite repricing efforts?
A:Ann Dennison explained that while stop-loss pricing and individual business repricing will reduce MLR, onetime benefits in 2025 and mix dynamics will temper year-over-year improvement. The outlook incorporates prudence given the elevated cost environment.
Q:Will the FTC settlement and legislation impact 2027 PBM earnings growth or revenue recognition?
A:Brian Evanko confirmed that the FTC settlement will not impact the 2027 financial outlook, and the long-term growth algorithm for PBS remains intact. There are no expected changes in revenue recognition despite the transition to a fee-based model.
Q:Can you elaborate on the specialty business growth drivers and biosimilar pipeline?
A:Brian Evanko highlighted 14% top-line growth in the specialty business, driven by inflammatory, asthma, and allergy categories. Biosimilars like HUMIRA have shown strong adoption, and the company expects $100 billion in specialty drug spend to face competition from biosimilars by 2030.
Q:Were the FTC settlement and legislative changes considered in the third-quarter outlook for the new rebate-free model?
A:David Cordani confirmed that the third-quarter outlook already accounted for the regulatory and legislative environment. The new model aligns with transparency, customer-first principles, and affordability goals.
Q:What is the outlook for Cigna Healthcare membership and funding mix in 2026?
A:Brian Evanko stated that membership is expected to remain flat at 18.1 million lives, with growth in U.S. employer and international health businesses offset by a decline in individual exchange customers. The group risk business is expected to remain stable, and growth in Select and middle market segments is anticipated.
Q:What is the AOI growth outlook for the Specialty and Care segment in 2026?
A:Ann Dennison stated that AOI growth for Specialty and Care is expected to be at the high end of the 8%-12% target, reflecting strong fundamentals and contributions from the Shields investment.
Q:Why is free cash flow conversion expected to be lower in 2026?
A:Ann Dennison explained that the $9 billion cash flow guidance for 2026 reflects a $600 million decline due to lower contributions from the PBS business, including the impact of large client renewals and investments. The rebate-free model will not impact the 2026 cash flow outlook.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the potential challenges or uncertainties in renegotiating deals with manufacturers for the new rebate-free model. Additionally, they did not provide specific details on the financial impact of the transition to the new model on working capital or the exact implications of the FTC settlement on future operations.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Cigna Group
Cigna Healthcare
Clearity
FTC
Today
access
affordability
authorization
benefit model
business
capability
client
condition
customer
demand
drug
environment
example
experience
fertility
health care
hospital
industry
innovation
investment
measure
medication
offering patient
outlook
partnership
pharmacy benefit
provider
settlement
site
solution
specialty
supply
tool
transformation
year
CI Transcript
The Cigna Group (CI) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
The Cigna Group (CI) Q1 2026 Earnings Call Transcript
Positive4-30
The earnings call summary indicates strong financial performance, with a 5% increase in adjusted income and 7% growth in adjusted revenues. The improvement in the Medical Care Ratio (MCR) also reflects effective cost management. Additionally, significant share repurchases demonstrate a commitment to shareholder returns. Despite the absence of operational updates and strategic initiatives, the solid financial results and shareholder-friendly actions suggest a positive sentiment. However, the lack of additional insights from the Q&A session slightly tempers the overall outlook, leading to a 'Positive' rating.
The Cigna Group (CI) Q4 2025 Earnings Call Transcript
Positive2-5
The earnings call reveals strong financial performance, exceeding revenue expectations and maintaining robust cash flow. Shareholder returns are significant, and strategic investments are in place. The Q&A section indicates alignment with regulatory expectations and optimistic growth in specialty services. While there are concerns about margin pressures and cash flow conversion, the overall sentiment remains positive due to strong fundamentals and strategic alignment. The positive outlook for the specialty business and shareholder returns further support a positive stock price reaction.
The Cigna Group (CI) Presents at UBS Global Healthcare Conference 2025 Transcript
Neutral11-12
CI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
